Disrupted Sialidase Cell Lines for Glycoprotein Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mammalian cell culture systems face challenges in maintaining consistent sialylation of glycoproteins, leading to variations in biological activity and stability due to sialic acid removal by sialidases, which affects the quality and consistency of therapeutic glycoproteins produced.
Innovation Solution
Development of cell lines with disrupted expression of chromosomally integrated nucleic acid sequences encoding plasma membrane-associated sialidases, such as those with amino acid sequences at least 90% identical to SEQ ID NO:4, to reduce sialidase activity and enhance sialylation of glycoproteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sialidase activity is present in mammalian cell culture systems, then glycoprotein production occurs, but sialic acid is removed from glycoproteins leading to decreased biological activity and increased serum clearance
Solution Approach 1:
The invention extracts and removes the harmful sialidase activity from the cell culture system by disrupting sialidase gene expression. This is achieved through introducing nucleic acid sequences that interfere with sialidase gene transcription or translation, thereby preventing sialic acid removal from glycoproteins and maintaining their biological activity and stability.
Solution Approach 2:
The invention converts the harmful effect of sialidase activity into a benefit by using the same cellular machinery to produce interfering RNAs that specifically target and silence sialidase genes. The cell's own gene expression system is harnessed to eliminate the harmful sialidase activity, transforming a detrimental process into a useful mechanism for improving glycoprotein quality.
2Productivity
If batch culture is used for glycoprotein production, then production efficiency is achieved, but nutrient consumption and product accumulation alter cellular environment causing glycosylation to decrease over time
Solution Approach 1:
The invention implements a feedback mechanism where the cellular response to nutrient depletion and stress signals is redirected toward maintaining glycosylation. By disrupting sialidase activity, the system compensates for environmental changes during batch culture, ensuring consistent sialylation levels even as nutrients are consumed and products accumulate.
Solution Approach 2:
The invention takes preliminary action by pre-disrupting sialidase gene expression before glycoprotein production begins. This proactive approach ensures that sialic acid removal is prevented from the outset, maintaining consistent glycosylation throughout the entire batch culture process rather than attempting to correct variations after they occur.
3Ease of manufacture
If standard mammalian cell lines are used, then production process is simple, but batch-to-batch variation occurs in glycoprotein sialylation
Solution Approach 1:
The invention changes a critical parameter of the cell line by disrupting sialidase gene expression. This genetic modification creates a new cell line variant that inherently maintains higher and more consistent sialylation levels. The change is stable and heritable, allowing the improved cell line to be used across multiple batches without requiring process adjustments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in glycoproteins with increased sialic acid content and improved stability, reducing batch-to-batch variations and enhancing the biological activity of recombinant glycoproteins produced, thereby ensuring quality and consistency in pharmaceutical production.
Implementation Method 1
disrupted expression of at least one chromosomally integrated nucleic acid sequence encoding a plasma membrane-associated sialidase
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention provides compositions and methods for the production of glycoproteins with enhanced sialylation. In particular, the invention provides cell lines comprising disrupted sialidase expression and methods of using the cell lines to produce glycoproteins with enhanced sialylation.